RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
BackgroundImmunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (combinations) are warranted. Simultaneously, risk asse...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 November 2023
|
| In: |
Frontiers in immunology
Year: 2023, Volume: 14, Pages: 1-18 |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2023.1286700 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2023.1286700 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1286700 
|
| Author Notes: | Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger and Dirk Hose |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1879384795 | ||
| 003 | DE-627 | ||
| 005 | 20240807084938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2023.1286700 |2 doi | |
| 035 | |a (DE-627)1879384795 | ||
| 035 | |a (DE-599)KXP1879384795 | ||
| 035 | |a (OCoLC)1425207339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Emde-Rajaratnam, Martina |d 1988- |e VerfasserIn |0 (DE-588)116096193X |0 (DE-627)1024350673 |0 (DE-576)506290433 |4 aut | |
| 245 | 1 | 0 | |a RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma |c Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger and Dirk Hose |
| 264 | 1 | |c 15 November 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 18 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.01.2024 | ||
| 520 | |a BackgroundImmunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (combinations) are warranted. Simultaneously, risk assessment is advisable as patient’s life expectancy varies between months and decades.MethodsWe first assess feasibility of RNA-sequencing in a multicenter trial (GMMG-MM5, n=604 patients). Next, we use a clinical routine cohort of untreated symptomatic myeloma patients undergoing autologous stem cell transplantation (n=535, median follow-up (FU) 64 months) to perform RNA-sequencing, gene expression profiling (GEP), and iFISH by ten-probe panel on CD138-purified malignant plasma cells. We subsequently compare target expression to plasma cell precursors, MGUS (n=59), asymptomatic (n=142) and relapsed (n=69) myeloma patients, myeloma cell lines (n=26), and between longitudinal samples (MM vs. relapsed MM). Data are validated using the independent MMRF CoMMpass-cohort (n=767, FU 31 months).ResultsRNA-sequencing is feasible in 90.8% of patients (GMMG-MM5). Actionable immune-oncological targets (n=19) can be divided in those expressed in all normal and >99% of MM-patients (CD38, SLAMF7, BCMA, GPRC5D, FCRH5, TACI, CD74, CD44, CD37, CD79B), those with expression loss in subfractions of MM-patients (BAFF-R [81.3%], CD19 [57.9%], CD20 [82.8%], CD22 [28.4%]), aberrantly expressed in MM (NY-ESO1/2 [12%], MUC1 [12.7%], CD30 [4.9%], mutated BRAF V600E/K [2.1%]), and resistance-conveying target-mutations e.g., against part but not all BCMA-directed treatments. Risk is assessable regarding proliferation, translated GEP- (UAMS70-, SKY92-, RS-score) and de novo (LfM-HRS) defined risk scores. LfM-HRS delineates three groups of 40%, 38%, and 22% of patients with 5-year and 12-year survival rates of 84% (49%), 67% (18%), and 32% (0%). R-ISS and RNA-sequencing identify partially overlapping patient populations, with R-ISS missing, e.g., 30% (22/72) of highly proliferative myeloma.ConclusionRNA-sequencing based assessment of risk and targets for first choice treatment is possible in clinical routine. | ||
| 700 | 1 | |a Beck, Susanne |d 1985- |e VerfasserIn |0 (DE-588)1164102362 |0 (DE-627)1028488866 |0 (DE-576)508378915 |4 aut | |
| 700 | 1 | |a Benes, Vladimir |e VerfasserIn |0 (DE-588)1155743911 |0 (DE-627)1017952639 |0 (DE-576)501828893 |4 aut | |
| 700 | 1 | |a Salwender, Hans |e VerfasserIn |0 (DE-588)1114928666 |0 (DE-627)869399993 |0 (DE-576)477578233 |4 aut | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Scheid, Christoph |e VerfasserIn |0 (DE-588)1075475244 |0 (DE-627)833299670 |0 (DE-576)443494495 |4 aut | |
| 700 | 1 | |a Hänel, Mathias |d 1964- |e VerfasserIn |0 (DE-588)17362295X |0 (DE-627)698532414 |0 (DE-576)134465970 |4 aut | |
| 700 | 1 | |a Weisel, Katja |d 1971- |e VerfasserIn |0 (DE-588)118014935 |0 (DE-627)079191975 |0 (DE-576)291668887 |4 aut | |
| 700 | 1 | |a Hielscher, Thomas |e VerfasserIn |0 (DE-588)1159594791 |0 (DE-627)1022977768 |0 (DE-576)50506068X |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Jauch, Anna |d 1959- |e VerfasserIn |0 (DE-588)1025525140 |0 (DE-627)722525362 |0 (DE-576)168357496 |4 aut | |
| 700 | 1 | |a Maes, Ken |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Bruyne, Elke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Menu, Eline |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Veirman, Kim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moreaux, Jérôme |e VerfasserIn |0 (DE-588)1158626851 |0 (DE-627)1020610077 |0 (DE-576)504256734 |4 aut | |
| 700 | 1 | |a Vanderkerken, Karin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seckinger, Anja |d 1980- |e VerfasserIn |0 (DE-588)134177371 |0 (DE-627)562118225 |0 (DE-576)278603734 |4 aut | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d Lausanne : Frontiers Media, 2010 |g 14(2023) vom: Nov., Artikel-ID 1286700, Seite 1-18 |h Online-Ressource |w (DE-627)657998354 |w (DE-600)2606827-8 |w (DE-576)343624834 |x 1664-3224 |7 nnas |a RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g month:11 |g elocationid:1286700 |g pages:1-18 |g extent:18 |a RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2023.1286700 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fimmu.2023.1286700 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240129 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 139824995 |a Hose, Dirk |m 139824995:Hose, Dirk |d 50000 |e 50000PH139824995 |k 0/50000/ |p 20 |y j | ||
| 998 | |g 134177371 |a Seckinger, Anja |m 134177371:Seckinger, Anja |d 50000 |e 50000PS134177371 |k 0/50000/ |p 19 | ||
| 998 | |g 1025525140 |a Jauch, Anna |m 1025525140:Jauch, Anna |d 910000 |d 911500 |d 50000 |e 910000PJ1025525140 |e 911500PJ1025525140 |e 50000PJ1025525140 |k 0/910000/ |k 1/910000/911500/ |k 0/50000/ |p 12 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 998 | |g 1159594791 |a Hielscher, Thomas |m 1159594791:Hielscher, Thomas |d 50000 |e 50000PH1159594791 |k 0/50000/ |p 9 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1164102362 |a Beck, Susanne |m 1164102362:Beck, Susanne |d 910000 |d 912000 |e 910000PB1164102362 |e 912000PB1164102362 |k 0/910000/ |k 1/910000/912000/ |p 2 | ||
| 998 | |g 116096193X |a Emde-Rajaratnam, Martina |m 116096193X:Emde-Rajaratnam, Martina |d 50000 |e 50000PE116096193X |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1879384795 |e 4471820672 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.3389/fimmu.2023.1286700"],"eki":["1879384795"]},"recId":"1879384795","relHost":[{"origin":[{"publisherPlace":"Lausanne","dateIssuedDisp":"2010-","dateIssuedKey":"2010","publisher":"Frontiers Media"}],"note":["Gesehen am 07.11.13"],"pubHistory":["1.2010 -"],"title":[{"title_sort":"Frontiers in immunology","title":"Frontiers in immunology"}],"disp":"RNA-sequencing based first choice of treatment and determination of risk in multiple myelomaFrontiers in immunology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"657998354","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["657998354"],"issn":["1664-3224"],"zdb":["2606827-8"]},"language":["eng"],"part":{"text":"14(2023) vom: Nov., Artikel-ID 1286700, Seite 1-18","extent":"18","volume":"14","pages":"1-18","year":"2023"}}],"physDesc":[{"noteIll":"Illustrationen","extent":"18 S."}],"name":{"displayForm":["Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger and Dirk Hose"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma","title_sort":"RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma"}],"note":["Gesehen am 29.01.2024"],"origin":[{"dateIssuedDisp":"15 November 2023","dateIssuedKey":"2023"}],"language":["eng"],"person":[{"role":"aut","given":"Martina","family":"Emde-Rajaratnam","display":"Emde-Rajaratnam, Martina"},{"role":"aut","given":"Susanne","family":"Beck","display":"Beck, Susanne"},{"role":"aut","given":"Vladimir","display":"Benes, Vladimir","family":"Benes"},{"display":"Salwender, Hans","family":"Salwender","role":"aut","given":"Hans"},{"role":"aut","given":"Uta","display":"Bertsch, Uta","family":"Bertsch"},{"role":"aut","given":"Christoph","family":"Scheid","display":"Scheid, Christoph"},{"given":"Mathias","role":"aut","display":"Hänel, Mathias","family":"Hänel"},{"family":"Weisel","display":"Weisel, Katja","given":"Katja","role":"aut"},{"given":"Thomas","role":"aut","display":"Hielscher, Thomas","family":"Hielscher"},{"role":"aut","given":"Marc-Steffen","family":"Raab","display":"Raab, Marc-Steffen"},{"role":"aut","given":"Hartmut","display":"Goldschmidt, Hartmut","family":"Goldschmidt"},{"display":"Jauch, Anna","family":"Jauch","role":"aut","given":"Anna"},{"display":"Maes, Ken","family":"Maes","given":"Ken","role":"aut"},{"family":"De Bruyne","display":"De Bruyne, Elke","role":"aut","given":"Elke"},{"given":"Eline","role":"aut","family":"Menu","display":"Menu, Eline"},{"family":"De Veirman","display":"De Veirman, Kim","given":"Kim","role":"aut"},{"display":"Moreaux, Jérôme","family":"Moreaux","role":"aut","given":"Jérôme"},{"family":"Vanderkerken","display":"Vanderkerken, Karin","given":"Karin","role":"aut"},{"given":"Anja","role":"aut","family":"Seckinger","display":"Seckinger, Anja"},{"family":"Hose","display":"Hose, Dirk","given":"Dirk","role":"aut"}]} | ||
| SRT | |a EMDERAJARARNASEQUENC1520 | ||